Patient with Guillain Barre Syndrome (GBS)

  • Steven Eastlack
  • Cassandra Armstead-Williams
  • Christopher H. Bailey
  • Lexus Trosclair
  • Farees Hyatali
  • Shilpa Patil
  • Harish Siddaiah
  • Anitha Senthil
  • Aaya Mouhaffel
  • Elyse M. CornettEmail author
  • Alan David Kaye


GBS is an acute ascending paralysis that can be fatal. This syndrome was first described in 1859 by JB Landry, but his clinical description was somewhat imprecise. It was not until Guillain, Barré, and Strohl published their findings in 1916 with more precise diagnostic criteria, that the medical community at large accepted GBS as an actual diagnosis. To properly honor all involved in the discovery of this clinical phenomenon GBS is sometimes called Landry-Guillain-Barre-Strohl syndrome. The precise pathophysiology of all GBS variants has never been fully explained. Therefore, GBS is characterized as a syndrome with multiple synonymous names, and labels, including but not limited to acute idiopathic polyneuritis, post-infectious polyneuropathy, and acute polyradiculitis. No matter what name is applied to the disease process when it affects a given patient, GBS is characterized by an acute, post-infectious, autoimmune process, that causes a paralysis that begins distally, then spreads medially and cephalad. And in the most fulminant cases, respiratory failure and an inability protect the airway develop.


Guillain Barre Syndrome Neurological disorder Autoimmune 


  1. 1.
    Pentland B, Donald SM. Pain in the Guillain-Barre syndrome: a clinical review. Pain. 1994;59(2):159–64.PubMedGoogle Scholar
  2. 2.
    Hughes RAC, Cornblath DR. Guillain-Barre syndrome. Lancet (London, England). 2005;366(9497):1653–66.Google Scholar
  3. 3.
    Lehmann HC, Hughes RAC, Kieseier BC, Hartung H-P. Recent developments and future directions in Guillain-Barre syndrome. J Peripher Nerv Syst. 2012;17(Suppl 3):57–70.PubMedGoogle Scholar
  4. 4.
    Frenzen PD. Economic cost of Guillain-Barré syndrome in the United States. Neurology. 2008;71(1):21–7.PubMedGoogle Scholar
  5. 5.
    Hahn AF. Guillain-Barre syndrome. Lancet (London, England). 1998;352(9128):635–41.Google Scholar
  6. 6.
    Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in Guillain-Barre syndrome. Neurology. 1997;48(2):328–31.PubMedGoogle Scholar
  7. 7.
    Goodfellow JA, Willison HJ. Guillain-Barre syndrome: a century of progress. Nat Rev Neurol. 2016;12(12):723–31.PubMedGoogle Scholar
  8. 8.
    Nguyen TP, Taylor RS. Guillain Barre Syndrome. [Updated 2019 Dec 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Available from:
  9. 9.
    Hauser S, Amato A. Harrison’s principles of internal medicine. In: Jameson J, Fauci A, Kasper D, Hauser S, Longo D, Loscalzo J, editors. Harrison’s principles of internal medicine. 20th ed. New York: McGraw-Hill; 2018. p. 3225–8.Google Scholar
  10. 10.
    Shy M. Goldman-Cecil medicine. In: Goldman L, Schafer A, editors. Goldman-Cecil medicine. Elsevier Saunders; 2016. p. 2529–31.Google Scholar
  11. 11.
    Ropper A, Wijdicks E, Truax B. Guillain-Barre syndrome. In: Guillain-Barre syndrome. Oxford University Press; 1991. p. 3–16, 22–30.Google Scholar
  12. 12.
    Dimachkie MM, Barohn RJ, et al. Guillain-Barré syndrome and variants. Neurol Clin. 2014;31(2):491–510.Google Scholar
  13. 13.
    Wakerley BR, Uncini A, Yuki N, GBS Classification Group, GBS Classification Group. Guillain-Barré and Miller Fisher syndromes—new diagnostic classification. Nat Rev Neurol. 2014;10(9):537–44.PubMedGoogle Scholar
  14. 14.
    Vriesendorp FJ. Guillain-Barré syndrome in adults: clinical features and diagnosis.
  15. 15.
    Walling AD, Dickson G. Guillain-Barré syndrome. Am Fam Physician. 2013;87(3):191–7.PubMedGoogle Scholar
  16. 16.
    Nguyen TP, Taylor RS. Guillain Barre syndrome. StatPearls Publishing; 2019. Accessed 16 Sept 2019.
  17. 17.
    Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31(2):491–510.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barre syndrome subtypes: where do we stand? Clin Neurophysiol. 2018;129(12):2586–93.Google Scholar
  19. 19.
    Doets AY, Jacobs BC, van Doorn PA. Advances in management of Guillain-Barre syndrome. Curr Opin Neurol. 2018;31(5):541–50.PubMedGoogle Scholar
  20. 20.
    Hughes RAC, Wijdicks EFM, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61(6):736–40.PubMedGoogle Scholar
  21. 21.
    Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78(13):1009–15.PubMedGoogle Scholar
  22. 22.
    Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barré syndrome. Hum Vaccin Immunother. 2018;14(11):2568–79.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Wijdicks EFM, Klein CJ. Guillain-Barre syndrome. Mayo Clin Proc. 2017;92(3):467–79.PubMedGoogle Scholar
  24. 24.
    Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2017;2:CD001798.PubMedGoogle Scholar
  25. 25.
    Kinboshi M, Inoue M, Kojima Y, et al. Pain in the acute phase of Guillain-Barré syndrome. Neurol Clin Neurosci. 2014;2(2):50–3.Google Scholar
  26. 26.
    Waldman S. Pain assessment tools for adults. Pain review. In: Pain review. 2nd ed. Philadelphia: Elsevier; 2009. p. 375–80.Google Scholar
  27. 27.
    Pandey CK, Bose N, Garg G, et al. Gabapentin for the treatment of pain in Guillain-Barré syndZrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg. 2002;95(6):1719–23.PubMedGoogle Scholar
  28. 28.
    Liu J1, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barré syndrome. Cochrane Database Syst Rev. 2013;20(10):CD009950.
  29. 29.
    Hughes RAC, Wijdicks EFM, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol. 2005;62(8):1194–8.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Steven Eastlack
    • 1
  • Cassandra Armstead-Williams
    • 2
  • Christopher H. Bailey
    • 3
  • Lexus Trosclair
    • 4
  • Farees Hyatali
    • 5
  • Shilpa Patil
    • 5
  • Harish Siddaiah
    • 5
  • Anitha Senthil
    • 6
  • Aaya Mouhaffel
    • 5
  • Elyse M. Cornett
    • 5
    Email author
  • Alan David Kaye
    • 7
  1. 1.LSU Health Sciences Center School of MedicineNew OrleansUSA
  2. 2.Department of AnesthesiologyLSU Health Sciences CenterNew OrleansUSA
  3. 3.Division of Pain Medicine, Department of Anesthesiology and Perioperative MedicineMayo ClinicPhoenixUSA
  4. 4.LSU Health ShreveportShreveportUSA
  5. 5.Department of AnesthesiologyLSU Health ShreveportShreveportUSA
  6. 6.Department of AnesthesiologyLahey Hospital and Medical CenterBurlingtonUSA
  7. 7.Department of AnesthesiologyLSU Health ShreveportShreveportUSA

Personalised recommendations